Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial

Br J Haematol. 2019 Mar;184(5):833-836. doi: 10.1111/bjh.15181. Epub 2018 Mar 12.
No abstract available

Keywords: allogeneic stem cell transplantation; chronic lymphocytic leukaemia; graft-versus-host disease prophylaxis; ofatumumab.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Allografts
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antigens, CD20*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunotherapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Male
  • Middle Aged

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20
  • ofatumumab